The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Increased Serum Levels of Carbohydrate Antigen 19-9 and Outcomes in Primary Sclerosing Cholangitis Patients Without Cholangiocarcinoma
Abstract
Background Carbohydrate antigen 19-9 (CA 19-9) is the serum marker used to diagnose cholangiocarcinoma (CCA) in patients with primary sclerosing cholangitis (PSC).Aim We investigated long-term outcomes in patients with PSC and elevated CA 19-9 levels without CCA.Methods A total of 166 PSC patients with serum levels of CA 19-9 without CCA followed at a single center from 1998 to 2011 were included. Patients with and without elevated CA 19-9 levels (greater than 129 U/ml) were compared.Results Fifty-two (31.3 %) of the 166 patients with PSC without CCA had elevated serum CA-19-9. Patients with elevated CA-19-9 were followed for a mean of 4 years and 12 (23.1 %) died. They were more likely to have higher PSC risk score (1.67 ± 1.30 vs. 0.91 ± 1.53, p = 0.003) and dominant strictures (31 (59.6 %) vs. 21 (18.4 %), p < 0.001). In 17/52 (32.7 %) of patients with elevated CA-19-9, no etiology was identified; cholestasis and cholangitis were associated with elevated levels in 24/52 (48.1 %) and 11/52 (21.2 %), respectively. There were 32 of 52 (62.5 %) that underwent orthotopic liver transplantation (OLT) in elevated CA 19-9 group compared to 66/114 (56.9 %) without (p = 0.66). The median OLT-free survival with elevated CA 19-9 was 9 years from PSC diagnosis compared to 14 years without. Although there was a trend, there was no significant difference in the OLT-free survival on Kaplan-Meier analysis (log rank p = 0.12).Conclusions Thirty-two percent of patients with PSC had elevated serum CA 19-9 in the absence of CCA. There was a trend towards shorter OLT-free survival in PSC patients with elevated CA-19-9.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Longitudinal series with repeated measures of CA 19-9 are contradictory 124,125 and increased levels are common in benign disease.126”
From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [126]
In the citing paper
“They are of limited diagnostic sensitivity and specificity, either alone or in combination.124,126,128,301,302”
From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [126]
Citations
Cites
Colorectal carcinoma antigens detected by hybridoma antibodies
Koprowski, H., Steplewski, Z., Mitchell, K., Herlyn, M., Herlyn, D., & Fuhrer, P. (1979) · Somatic Cell Genetics · doi:10.1007/bf01542654 · Cited by 1,364
Incidence and Risk Factors for Cholangiocarcinoma in Primary Sclerosing Cholangitis
Burak, K., Angulo, P., Pasha, T. M., Egan, K., Petz, J., & Lindor, K. D. (2004) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2004.04067.x · Cited by 557
Prevalence of Primary Sclerosing Cholangitis in Patients With Ulcerative Colitis
Olsson, R., Danielsson, Å., Järnerot, G., Lindström, E., Lööf, L., Rolny, P., Rydén, B.-O., Tysk, C., & Wallerstedt, S. (1991) · Gastroenterology · doi:10.1016/0016-5085(91)70019-t · Cited by 426
High lifetime risk of cancer in primary sclerosing cholangitis
Claessen, M. M. H., Vleggaar, F. P., Tytgat, K. M. A. J., Siersema, P. D., & van Buuren, H. R. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2008.08.013 · Cited by 412
Levy, C., Lymp, J., Angulo, P., Gores, G. J., Larusso, N., & Lindor, K. D. (2005) · Digestive Diseases and Sciences · doi:10.1007/s10620-005-2927-8 · Cited by 339
Cholangiocarcinoma in patients with primary sclerosing cholangitis: A multicenter case-control study
Chalasani, N., Baluyut, A., Ismail, A., Zaman, A., Sood, G., Ghalib, R., McCashland, T. M., Reddy, R. K., Zervos, X., Anbari, M. A., et al. (2000) · Hepatology · doi:10.1002/hep.510310103 · Cited by 336
Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice
Mann, D., Edwards, R., Ho, S., Lau, W., & Glazer, G. (2000) · European Journal of Surgical Oncology (EJSO) · doi:10.1053/ejso.1999.0925 · Cited by 294
Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis
Ramage, J. K., Donaghy, A., Farrant, J. M., Iorns, R., & Williams, R. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)90462-x · Cited by 279
Primary Sclerosing Cholangitis, Inflammatory Bowel Disease, and Colon Cancer
Broomé, U., & Bergquist, A. (2006) · Seminars in Liver Disease · doi:10.1055/s-2006-933561 · Cited by 244
CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions
Marrelli, D., Caruso, S., Pedrazzani, C., Neri, A., Fernandes, E., Marini, M., Pinto, E., & Roviello, F. (2009) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2008.12.031 · Cited by 241
Cited by
Razumilava, N., & Gores, G. J. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61903-0 · Cited by 1,729
EASL Clinical Practice Guidelines on sclerosing cholangitis
Chazouilleres, O., Beuers, U., Bergquist, A., Karlsen, T. H., Levy, C., Samyn, M., Schramm, C., & Trauner, M. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.05.011 · Cited by 419
Aabakken, L., Karlsen, T., Albert, J., Arvanitakis, M., Chazouilleres, O., Dumonceau, J.-M., Färkkilä, M., Fickert, P., Hirschfield, G., Laghi, A., et al. (2017) · Endoscopy · doi:10.1055/s-0043-107029 · Cited by 255
Trikudanathan, G., Navaneethan, U., Njei, B., Vargo, J. J., & Parsi, M. A. (2014) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2013.09.015 · Cited by 203
Self-citationvan Walraven, C., & McAlister, F. A. (2015) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2015.07.006 · Cited by 142
Metadata
- Authors
- Venkatesh, P. G. K., Navaneethan, U., Shen, B., & McCullough, A. J.
- Affiliations
- Cleveland Clinic (US)
- Corresponding author
- Navaneethan, Udayakumar
- Venue
- Digestive Diseases and Sciences
- Published
- 2012-09-25
- Volume
- 58
- Issue
- 3
- Pages
- 850-857
- ISSN
- 0163-2116 (ISSN-L)
- 1573-2568
- OpenAlex
- W1973957643
- Cited by
- 49
- References
- 26
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 1 · 2023: 2 · 2022: 2 · 2021: 1 · 2020: 3 · 2019: 1 · 2018: 2 · 2017: 8 · 2016: 5 · 2015: 8 · 2014: 8 · 2013: 2
- FWCI
- 3.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Digestive Diseases and Sciences (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Cleveland Clinic
- American College of Gastroenterology
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Health Sciences › Medicine › Gastroenterology › Gallbladder and Bile Duct Disorders
- Keywords
- primary sclerosing cholangitis, carbohydrate antigen 19-9, orthotopic liver transplantation, cholestasis, cholangitis, long-term outcomes, serum tumor markers
- MeSH terms
- Adult, Female, Humans, Male, Middle Aged, Risk Factors, Cholangitis, Sclerosing, Multivariate Analysis, Proportional Hazards Models, Liver Transplantation, Treatment Outcome, Cholangiocarcinoma, CA-19-9 Antigen, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Increased Serum Levels of Carbohydrate Antigen 19-9 and Outcomes in Primary Sclerosing Cholangitis Patients Without Cholangiocarcinoma. https://app.cochat.ai/papers/10.1007/s10620-012-2401-3
- The paper
- Venkatesh, P. G. K., Navaneethan, U., Shen, B., & McCullough, A. J. (2013). Increased Serum Levels of Carbohydrate Antigen 19-9 and Outcomes in Primary Sclerosing Cholangitis Patients Without Cholangiocarcinoma. Digestive Diseases and Sciences. https://doi.org/10.1007/s10620-012-2401-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.